#clinical-trials

#clinical-trials

Novo Nordisk plans to deploy advanced artificial intelligence capabilities to analyze complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient.

The study published in the Lancet analyzed data from 381 patients with platinum-resistant ovarian cancer, revealing a 35% reduction in the risk of death among those treated with relacorilant compared to usual care.

One theory is that by slowing the rate of biological ageing, it may be possible to prevent or mitigate age-related illness, meaning people have more years of good health. A study carried out by researchers in the US and including funding from the confectionery manufacturer Mars suggests a daily multivitamin could help slow some markers of biological ageing – although what that means in terms of health remains unclear.

Ozempic and other GLP-1 drugs have had a major impact in their short time on the market-currently, one in eight Americans say that they have been on GLP-1 drugs. As tens of millions of people take these medications, anecdotal evidence has emerged that they have a positive effect on alcohol abuse and drug addiction. Researchers are starting to run trials of the drugs for these purposes, and some speculate that GLP-1 drugs could even affect addiction behaviors such as gambling and online shopping.

When Lisa Dutton was declared free of breast cancer in 2017, she took a moment to celebrate with family and friends, even though she knew her cancer journey might not be over. As many as one-third of people whose breast tumours are cleared see the disease come back, sometimes decades later. Many other cancers are known to recur in the years following an initial treatment, some at much higher rates.

However, it is regrettable that an organisation such as the World Health Organization appears willing to promote the incorporation of traditional and other medicines into mainstream practice by leaning heavily on emotive language heritage, tradition, and the sharing of local resources rather than on clinical evidence. Then it appears to contradict itself by saying that it doesn't support it if there isn't robust and reliable evidence.

London's position as Europe's leading clinical research hub generates profound impacts extending far beyond laboratory walls and hospital wards. Hundreds of London trials running simultaneously create a sophisticated ecosystem connecting pharmaceutical companies, research institutions, healthcare providers, and most importantly, thousands of patients seeking access to innovative treatments whilst contributing to medical advancement. This ecosystem delivers tangible economic value whilst simultaneously addressing patient needs that conventional healthcare often cannot meet.

The biotech company, which is headquartered in Milpitas, turned in a Chapter 7 filing, meaning that it seeks liquidation, rather than reorganization. The document is so sparse that it prompted a request from the court's deputy clerk for more information. But it depicts a company in dire straits: ASC Therapeutics estimates that it has between $100,000 and $500,000 in assets and between $10 million and $50 million in liabilities.

There's a commitment that patients make to the clinical trials ... Here, you've broken a commitment to those individuals,

Cuba is battling a wave of mosquito-borne illnesses, with the country's top epidemiologist warning that nearly one-third of the population has been impacted, with large numbers of workers taken ill. On Thursday, fumigators armed with fogging machines probed alleys and crowded buildings in parts of the capital Havana, among the hardest hit by mosquito-borne viruses including dengue and chikungunya, authorities said.

The groundbreaking clinical trial, described on 31 October in the American Journal of Human Genetics, will deploy an offshoot of the CRISPR-Cas9 gene-editing technique called base editing, which allows scientists to make precise, single-letter changes to DNA sequences. The study is expected to begin next year, after its organizers spent months negotiating with US regulators over ways to simplify the convoluted path a gene-editing therapy normally has to take before it can enter trials.

The announcement of a positive result from a major clinical trial is an incredibly exciting moment in the world of medicine. It's a validation of years of painstaking research, a potential new tool for doctors, and, most importantly, a powerful new source of hope for patients and their families. As a physician or a researcher, the desire to share this exciting news with the public is a natural one.

An SF-based biotech company is working on a safer, reformulated version of MDMA, better known as molly' or ecstasy,' and we're not tripping when we say they just won FDA approval to begin Phase 1 clinical trials. We have occasionally covered Bay Area medical research into MDMA, the street drug known as ecstasy or molly, and perhaps a little too enthusiastically at that.

But last Wednesday was a day unlike any other. I cried with every single patient, Sung says. It just was this crazy feeling that, for the patients and families, almost can't feel real. That day the results of important phase 1/2 clinical trials had finally been released: an experimental gene therapy drug was the first treatment shown to slow the progression of Huntington's disease.

Recent headlines warning of concerns such as heart risks or danger to teenagers have put a new spotlight on a diet trend that has long been the popular epitome of a healthy lifestyle: intermittent fasting. Intermittent fasting's image has been deeply tarnishedand quite rightly so, says Stefan Kabisch, a physician at the endocrinology and metabolic medicine department at ChariteUniversity Medicine Berlin. The hype was never really backed up by good data in humans.

We've still got the best universities, we've got some of the best scientists in the world, but it's not a good place to do the development work for medicines. It's an expensive place to operate, and it's a terrible place to sell medicines.

The simple truth is that medicine is always multimodal. A physician's mind doesn't travel in a straight line, drifting from the patient's story to the CT image, lab values, and clues in a physical exam.

"Dancing molecules," the promising new treatment for acute spinal cord injuries developed at Northwestern University, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA).

Deep-brain stimulation involves inserting thin wires through two small holes in the skull into a region of the brain associated with movement. The hope is that by delivering electrical pulses to the region, the implant can normalize aberrant brain activity and reduce symptoms.